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specific antigen (PSA), an indicator of
prostate cancer, had plummeted. The
patient admitted he was taking PC-SPES,
an herbal remedy derived from nine sepa-
rate herbs and mushrooms that is sold
over the Internet. DiPaola soon began to
notice similar effects in other patients tak-
ing PC-SPES. He presented the case to
Michael Gallo, the institute's associate
director for basic science, who recalls: "I
said, 'We've got an estrogen here. Let's
take a look at these herbs."'
DiPaola and Gallo turned their atten-
tion toward the men, conducting a clinical
trial involving eight cancer patients taking
the herbal remedy. They found that PC-
SPES causes a decrease in testosterone and
PSA, along with other symptoms of estro-
gen use. The researchers then enlisted
George Lambert, a clinical pharmacologist
at the NIEHS Environmental and
Occupational Health Sciences Institute in
Piscataway, New Jersey, to examine PC-
SPES for estrogenic activity.
A yeast-based assay used by Lambert
confirmed Gallo and DiPaola's suspicions
that PC-SPES acts as an estrogen. "This is
as potent as a drug," says DiPaolo. Says
Gallo, "It was the collaboration of the
expertise of these two centers that allowed
us to make this discovery. This is the type
of bioassay that should be done on herbal
products." The three researchers and nine
other colleagues reported their findings in
the 17 September 1998 issue of the New
EnglandJournalofMedicine (NEJM).
Journal editors Marcia Angell and
Jerome Kassirer used the report as a spring-
board for their editorial calling on the
Food and Drug Administration (FDA) to
require the same rigorous testing of alter-
native medicines that it requires ofconven-
tional drugs. PC-SPES, like other plant-
derived substances, vitamins, minerals, and
amino acids, is considered a dietary supple-
ment. The FDA regulates supplement
labeling but requires no testing.
The NEJM report hit a nerve among
those who view herbal remedies as distinct-
ly different-and safer-than their syn-
thetic cousins. "I believed there was a pos-
sibility of a potential cure with this," says
Mario Menelly, a PC-SPES user and sub-
ject in DiPaola's clinical trial. "It's nothing
but herbs. It shouldn't hurt me." The arti-
cle prompted a spate ofletters to the editor
from both sides of the issue, scheduled to
be published in a future issue ofNEJM.
In the long run, PC-SPES may be no
more harmful than conventional treat-
ment, but nobody knows for sure. Even
proponents ofherbal remedies recommend
more clinical trials. "We need large-scale
studies," says Sophie Chen, a professor of
medicine at New York Medical College in
Valhalla, who developed PC-SPES five
years ago. "I would like to see it become a
prescription medicine."
The yeast assay used to screen PC-
SPES is among several developed in recent
years that can measure estrogenic activity
quickly and inexpensively. For a half-cen-
tury, the only assay for estrogen required
mice. Scientists fed mice the substance
under study for several days, then sacrificed
them and weighed their uteruses.
Estrogenic substances cause the uterus to
enlarge.
Mice assays are still considered the gold
standard-DiPaolo and Gallo followed the
yeast screening with a mouse assay-but
may soon be replaced with yeast and other
cellular assays. "It's less expensive," explains
Elizabeth Jeffery, an associate professor of
nutritional toxicology at the University of
Illinois at Urbana-Champaign. "It's less
labor-intensive. It's much more rapid." The
yeast assay initially was used to screen PC-
SPES for estrogen that binds to alpha
receptors, which are found primarily in
reproductive tissue. A few years ago,
researchers discovered a second receptor,
beta, that binds to estrogen in the brain,
bone, kidneys, and other organs. Lambert's
group is now developing a greater array of
hormone receptor assays to screen the
herbal remedy with beta receptors.
The yeast assay was constructed to sim-
ulate response of the human estrogen
receptor system when exposed to an estro-
genic mixture. When an estrogenic sub-
stance is added to the medium, the yeast
proliferate. If the substance is not estro-
genic, the yeast die. Like other screening
assays, the yeast assay has limitations. It will
not indicate activity in compounds that
become estrogenic only after they're oxi-
dized in the body, such as the pesticide
methoxychlor. Differences in the perme-
ability ofyeast and human cell membranes
also could confound results. "Something
may not be able to get through the cell wall
ofyeast even though it gets through the cell
membrane ofhumans," Lambert says.
To some cancer patients, like Mario
Menelly, yeast assays and clinical trials
don't mean a thing. Menelly is sticking
with an unregulated mixture ofherbs, even
if it causes the same side effects as conven-
tional, hormonal drugs. "It's only herbs,"
he says. "It comes from the earth."
His attitude is common. More than
halfofU.S. adults use dietary supplements,
according to the FDA. Estimates of alter-
native-therapy usage among cancer
patients range from 5% to 60%. "This
isn't just a fad that'll go away in two
months," says John Cardellina, director of
botanical science for the Council for
Responsible Nutrition, a trade organiza-
tion representing manufacturers of dietary
supplements. Cardellina laments the lack
of information about dietary supplements
for both consumers and physicians.
"Doctors do not know enough about
botanical products," he says. "They don't
know what to expect in terms of efficacy
and side effects. This [NEJM report] may
get oncologists to look at PC-SPES and
what it can do."
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